[{"id":"ee98277b-261b-44a8-a033-c2fa8d278537","acronym":"THETIS","url":"https://clinicaltrials.gov/study/NCT03997474","created_at":"2021-07-29T18:53:19.522Z","updated_at":"2024-07-02T16:35:24.579Z","phase":"Phase 1/2","brief_title":"ATL001 in Patients With Metastatic or Recurrent Melanoma","source_id_and_acronym":"NCT03997474 - THETIS","lead_sponsor":"Achilles Therapeutics UK Limited","biomarkers":" PD-L1 • BRAF • IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ATL 001"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/15/2019","start_date":" 08/15/2019","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-01-04"}]